Previous studies have shown that intra-tumoral injection of CXCL9, CXCL10, CXCL11, or their fusion proteins efficiently induces the recruitment of CD8+ T cells and NK cells via CXCR3 and suppresses tumor growth in various murine cancer models such as lung cancer, colon cancer, kidney cancer, melanoma, and glioma [40,41]. This evidence concerns the gene CXCL9 and melanoma.